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synergistically inhibit HIV infection in CD4+ T cells
by up-regulating ABCA1-mediated cholesterol
efflux
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Background: Retinoic acids regulate the reverse cholesterol transport by inducing the ATP binding cassette
transporter A1 (ABCA1) dependent cholesterol efflux in macrophages, neuronal as well as intestine cells. In the
present study, we aim to test the effect of all trans retinoic acid (ATRA) on ABCA1 expression in human CD4+ T
cells and the involvement of cholesterol in ATRA mediated anti-HIV effect.
Results: Treatment with ATRA dramatically up-regulated ABCA1 expression in CD4+ T cells in a time and dose
dependent manner. The expression of ABCA1 paralleled with increased ABCA1-dependent cholesterol efflux. This
induction was dependent on T cell receptor (TCR) signaling and ATRA failed to induce ABCA1 expression in resting
T cells. Moreover, ATRA and liver X receptor (LXR) agonist-TO-901317 together had synergistic effect on ABCA1
expression as well as cholesterol efflux. Increased ABCA1 expression was associated with lower cellular cholesterol
staining. Cells treated with either ATRA or TO-901317 were less vulnerable to HIV-1 infection. Combination of
retinoic acid and TO-901317 further inhibited HIV-1 entry and their inhibitory effects could be reversed by
cholesterol replenishment.
Methods: ABCA1 RNA and protein were determined by real-time PCR and immuno blot methods in cells treated
with ATRA. Cholesterol efflux rate was measured in cells treated with ATRA and TO-901317.
Conclusions: ATRA up-regulates ABCA1 expression and cholesterol efflux in CD4+ T cells and combination of ATRA
and liver X receptor (LXR) agonist further enhanced these effects. Increased cholesterol efflux contributed to
reduced HIV-1 entry, suggesting that anti-HIV effect of ATRA is mediated through ABCA1.
Keywords: ABCA1, ATRA, retinoic acid, TO-901317, RAR, RXR, LXR, cholesterol efflux, HIV-1, CD4+ T cellsBackground
Lipid components of the cell membrane are important for
normal cell function. Cholesterol is one of the most im-
portant regulators of lipid organization. It is also the major
component of lipid rafts, which are the centers for assem-
bling of signaling molecules and membrane protein traf-
ficking [1]. Lipid rafts are also believed to be sites for
HIV-1 entry, assembly and budding [2-5]. Cholesterol on
both viral and cellular membrane is required for successful* Correspondence: vnatarajan@mail.nih.gov
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reproduction in any medium, provided the orHIV-1 infection. Down-regulation of cholesterol from
HIV-1 target cells dramatically inhibited both HIV-1 entry
and virus particle production [6,7]. Removal of the choles-
terol from HIV-1 with cholesterol extraction reagent β-
cyclodextrin resulted in a dose-dependent inactivation of
the virus [8].
Cellular cholesterol is maintained in a narrow range by
cholesterol up-take and efflux. Accumulation of choles-
terol can have profound effects on cellular functions,
which can cause serious diseases, like atherosclerosis [9].
ABCA1, a member of the ATP-binding cassette trans-
porter protein family (ABCs), plays an essential role in
controlling the cellular cholesterol level by mediating thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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A1 (apo-A1) [10]. ABCA1 is a ubiquitously expressed
plasma membrane protein. ABCA1 mutation and defi-
ciency is associated with increased tissue and cellular
cholesterol, atherosclerosis and Tangier disease [11-15].
Regulations of ABCA1 and lipid efflux have been stud-
ied extensively in macrophages. LXR and LXR ligand
oxysterol play a major role in ABCA1 induction and
cholesterol efflux in macrophages [16-18]. Retinoic acids
by binding to retinoic acid receptor (RAR) and retinoid
X receptor (RXR) are also known to induce ABCA1 ex-
pression in macrophages [16,19,20]. Retinoic acid is
involved in multiple T cell functions and very little is
known about the regulation of ABCA1 in T cells. In this
study, we investigated the regulation of ABCA1 expres-
sion and cholesterol efflux in T cells by ATRA. Our
results demonstrated that ATRA specifically up-regu-
lated ABCA1 but not ABCA3 or ABCG1 expression.
ABCA1 mediated free cholesterol efflux, which contrib-
uted to significant reduction of HIV-1 entry into T cells.
Furthermore, ATRA and TO-901317, an LXR agonist,
functioned synergistically to further enhance ABCA1 ex-
pression and inhibit HIV-1 infection in T cells.
Results
Up regulation of ABCA1 in CD4+ T cells by ATRA
Retinoic acids have been shown to influence the function
of T cells while its effect in T cells has not been fully
understood [21,22]. PMA and PHA or antibodies against
CD3 and CD28 are used to activate T cells in vitro. PHA
and PMA activate T cells by binding to cell surface re-
ceptor including TCR and activating protein kinase C re-
spectively. Bindings of antibodies against CD3 and CD28
to corresponding receptor activate T cells by mimicking
the intracellular signals generated by ligation of TCR-
CD3 [23]. To assess the effect of ATRA on gene expres-
sions, we treated anti-CD3/CD28 antibody primed
CD4+ T cells from healthy donors with or without
ATRA, and RNAs from these cells were isolated and
used for gene array analysis and identified ABCA1 as
one of the most up regulated gene by ATRA treatment.
To confirm this result, changes of ABCA1 mRNA
levels in response to ATRA treatment was assessed by
quantitative real-time PCR following reverse transcrip-
tion. Consistent with gene array results, ABCA1 mRNA
was dramatically up regulated by ATRA treatment
(Figure 1A). Since ABCA1 RNA stability was not
affected in response to ATRA treatment (data not
shown), the up-regulation of ABCA1 is at the transcrip-
tion level. This is consistent with previous findings seen
in macrophages [20]. The effect of ATRA on ABCA1
protein expression was also analyzed by western blot. As
shown in Figure 1B, the basal expression of ABCA1 pro-
tein is barely detectable in primary human CD4+ T cells.In response to the stimulation with ATRA, ABCA1 pro-
tein level significantly increased, which parallels with the
induction of its mRNA. The induction of ABCA1 ex-
pression was both time- and dose-dependent. ATRA
up-regulated ABCA1 RNA by 11 fold at 0.1 μM, and at
concentrations of 1 μM and 5 μM could induce ABCA1
RNA expression over 100 times (Figure 1C). As early as
4 hours after ATRA treatment, the expression of ABCA1
mRNA increased by almost 3 times and by 24 hrs of
treatment, the stimulation of ABCA1 expression reached
maximum (Figure 1D).
ABCA1 induction by ATRA is dependent on TCR signaling
ATRA has only marginal effect on ABCA1 expression in
resting CD4+ T cells. Upon T cell activation with anti-
CD3 and CD28 antibodies, the expression of ABCA1
increased 100 folds in response to ATRA treatment.
PMA/PHA treatment together with ATRA increased the
ABCA1 expression by 400 folds (Figure 1E). Whereas,
without ATRA, T cell activation alone had little effect.
These results indicate that both ATRA and TCR signal-
ing are required for ABCA1 expression and TCR signal-
ing is essential for ATRA effect on ABCA1 up
regulation. During T cell activation, MAP kinase path-
ways including ERK pathway are affected [24]. ERK sig-
naling pathway has been shown to play a role in ABCA1
mRNA and protein stability in macrophages [25]. When
different MAP kinase inhibitors were tested on ABCA1
mRNA levels, none of the inhibitors by themselves had
any effect on ABCA1 mRNA expression (data not
shown). However, ERK inhibitor along with ATRA had
significant stimulatory effect on ABCA1 (Figure 1F). The
mechanism of up regulation of ABCA1 mRNA in CD4+
T cells by ERK inhibitor is not known yet but it could
stabilize newly synthesized ABCA1 mRNA and protein
as in macrophages [25].
ABCA1 is a ubiquitously expressed plasma membrane
protein. It belongs to a family of proteins called ATP-
binding cassette transporter (ABCs). There are 49
human ABC proteins. They are classified into seven sub-
families, from A to G based on the similarity in their
gene structure, sequence or phylogenesis. Besides
ABCA1, ABCG1 is also capable of mediating cholesterol
efflux [10]. Also, ABCA1 and ABCG1 appear to share a
similar mechanism of regulation. Both of them are tar-
gets of retinoid X receptor (RXR)/ LXR in macrophages
[16,26]. Result presented in Figure 1A show that in CD4
+ T cells, ATRA specifically induced RNA expression of
ABCA1, while it has only minor effect on ABCG1 RNA
expression. Similar regulation was also observed in
macrophages [19]. The mechanism of regulation of
ABCA1 and ABCG1 expression could be potentially dif-
ferent. The expression of two other genes from the same


































































































































































Figure 1 ATRA induces ABCA1 expression in human primary CD4+ T cells. A) Human CD4+ T cells isolated from healthy donors were
primed with anti-CD3 and anti-CD28 antibodies and treated with DMSO or 1 μM of ATRA for 3 days. RNA isolation, reverse transcription, and real
time PCR were done as described in Methods. ABCA1 RNA expression was normalized to GAPDH RNA expression, and relative RNA fold changes
compared to that from DMSO treatment were plotted. B) ABCA1 proteins were detected by Western blot with antibody specific to human
ABCA1 as described. GAPDH was used as a loading control. C) ABCA1 RNA expression in response to treatment with different concentrations of
ATRA. D) ABCA1 RNA expression in response to treatment with ATRA for various lengths of times. E) CD4+ T cells were activated with anti-CD3
and anti-CD28 antibody or PMA and PHA and were also treated with either DMSO or ATRA. ABCA1 RNA level was analyzed by real-time PCR. F)
Anti-CD3/CD28 antibody primed CD4+ T cells were treated with DMSO or 10 μM of U0126 for 2 hours and then treated with or without ATRA.
ABCA1 RNA level was quantitated by real-time PCR. Results are representative of three experiments with cells from three different donors.
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sponse to ATRA treatment (Figure 1A).
Increased ABCA1 gene expression parallels with elevated
cellular cholesterol efflux
ABCA1 plays an essential role in controlling cellular
cholesterol level by mediating cellular free cholesterol ef-
flux to lipid-free apo-A1 [10]. To determine whether
ABCA1-mediated cholesterol efflux increased in re-
sponse to ATRA treatment, anti-CD3/CD28 antibody
primed CD4+ T cells were incubated in the absence or
presence of ATRA. Cells were then labeled with [3 H]-
cholesterol and free cholesterol efflux to Apo-A1 was
determined (Figure 2). As expected, cholesterol efflux toApo-A1 increased in response to ATRA treatment by
about 40%. The increase in cholesterol efflux parallels
the induction of ABCA1 expression indicating that the
increased cholesterol efflux is mediated by ABCA1.
Retinoic acid and LXR ligand – TO-901317 have
synergistic effects on ABCA1 expression and cholesterol
efflux
ABCA1 is regulated mainly at the transcription level.
LXR and RXR, and their ligands are the most potential
activators for ABCA1 expression and lipid efflux [20].
They up-regulate ABCA1 mRNA expression in a wide
range of cells including macrophages, neuronal and in-



































Figure 2 ATRA stimulates ABCA1-mediated cholesterol efflux.
Activated CD4+ T cells were treated with DMSO or 5 μM ATRA and
loaded with radioactive cholesterol for 24 hours and cholesterol
efflux to apo-A1 was estimated after 4 hours incubation in
cholesterol efflux medium. The result is presented as mean± the
standard deviation (SD; n = 3). * p< 0.05 versus cells treated with
DMSO.
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by 4 nucleotides (DR4) on the proximal promoter of
ABCA1 and up-regulate ABCA1 gene expression. Com-
bination of retinoic acid with natural oxysterols has been
shown to have the most effect on ABCA1 levels
[16,29,32,33]. It will be interesting to know whether
ATRA and LXR agonist TO-901317 have synergistic ef-
fect on ABCA1 expression in T cells. As shown in
Figure 3 A and B, ATRA or TO-901317 increased
ABCA1 expression at RNA and protein level in primary
CD4+ T cells, and the combination of ATRA and
TO-901317 further enhanced ABCA1 expression. Treat-
ment of Jurkat cells, a CD4+ T cell line, with ATRA and
TO-901317 increased ABCA1 expression by 27- and
20-fold, respectively (Figure 3C) and treatment with
both ATRA and TO-901317 increased ABCA1 expres-
sion by almost 300 fold showing synergistic effect of
ATRA and TO-901317 on ABCA1 expression in T cells
(Figure 3D).
Next we investigated the synergistic effect of ATRA and
TO-901317 on free cholesterol efflux to apo-A1 in Jurkat
cell. By 48 hours, ATRA alone increased cholesterol efflux
by 50%, whereas TO-901317 increased cholesterol efflux
by 40%. Combination of ATRA and TO-901317 further
increased cholesterol efflux by about 2-fold (Figure 4A).Parallel increases in ABCA1 level and cholesterol efflux
strongly suggest that the cholesterol efflux is mediated by
ABCA1.
Increased cholesterol efflux should lower cellular chol-
esterol level. To confirm this, we performed cellular
cholesterol staining with Filipin III. Filipin III is a polyene
antibiotic that interacts with cholesterol but not with
cholesteryl esters. The staining was found mostly in the
plasma membrane (Figure 4B). This is in line with the
cholesterol concentration being higher in the plasma
membrane than other cellular membranes. Some staining
could also be detected in the endocytic-recycling com-
partment, a perinuclear compartment [34]. Upon ATRA
treatment, the Filipin staining was reduced. Similar result
was also observed in cells treated with TO-901317
(Figure 4B and 4C) and together, ATRA and TO-901317
reduced cholesterol staining by 50%. To replenish chol-
esterol to cells treated with ATRA and/or TO-901317,
cells were incubated in the medium containing water-
soluble cholesterol for 1 hr and stained with Filipin.
Results in Figure 4 D shows that cholesterol could be
replenished in cells treated with ATRA and or TO-901317.
Taken together, these results demonstrated that ATRA
and TO-901317 have synergistic effect on reducing cel-
lular cholesterol level in T cells by up-regulation of
ABCA1 expression and ABCA1-dependent cholesterol
efflux.
ATRA and TO-901317 synergistically inhibit HIV-1
infection by reducing cellular cholesterol level
Cholesterol is important for a number of virus infec-
tions, including HIV-1 [2-5,35,36]. Cholesterol on both
viral and cellular membrane is required for successful in-
fection of HIV-1. Removal of cholesterol from HIV-1
with cholesterol extraction reagent ß-cyclodextrin
resulted in inactivation of the virus [8]. ATRA has in-
hibitory effect on HIV-1 infection [37-40]. However, the
mechanism of ATRA induced HIV-1 inhibition has not
been fully understood. We hypothesize that ATRA could
inhibit HIV-1 infection by reducing the cellular choles-
terol. To test this hypothesis, we first investigated the ef-
fect of ATRA on HIV-1 infection using 1G5 cells, a
reporter Jurkat cell line with integrated luciferase gene
under the control of HIV-1 LTR promoter. 1G5 cells
have low basal level of luciferase expression and could
be activated by HIV-1 infection or by HIV-1 tat [41].
This cell line has been used to measure the HIV replica-
tion since a good correlation has been shown between
the level of viral replication and the level of luciferase
activity.
ATRA and TO-901317 up-regulated ABCA1 expres-
sion and decreased cellular cholesterol in Jurkat cells
and in 1G5 cells to the similar level (data not shown).
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Figure 3 ATRA and TO-901317 synergistically induce ABCA1 expression. A) Primed human CD4+ T cells were incubated with 1 μM of ATRA
and 1 μM of LXR-agonist TO-901317 for 2 days. ABCA1 mRNA was measured and normalized to the level of GAPDH mRNA and relative RNA fold
changes compared to that from DMSO treated cells were plotted. Results are representative of three independent experiments. Data are
presented as mean± the standard deviation. B) ABCA1 and GAPDH proteins were detected as described in Methods. C) The intensity of the
ABCA1 protein bands in (B) was quantified and normalized to that of GAPDH. The relative intensity compared to DMSO treatment was plotted.
Results are representative of three independent experiments. Data are presented as mean± the standard deviation. D) and E) The synergistic
effects of 5 μM of ATRA and 1 μM of TO-901317 on ABCA1 RNA and protein expression, respectively, in Jurkat cells. F) The intensity of the bands
representing ABCA1 protein in (E) was quantified and normalized to that of GAPDH protein. The relative intensity compared to DMSO treatment
was plotted.
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absence of ATRA for 3 days and infected with HIV-1.
One hour after virus infection, virus entry was detected
by quantitative PCR using primers that detect the accu-
mulation of early R/U5 viral DNA from reverse tran-
scription [42]. Compared with control, entry of HIV-1
virus into ATRA treated cells was reduced by 30%
(Figure 5A). Cholesterol replenishment to ATRA treated
cells reversed the inhibitory effect on HIV-1 entry indi-
cating that the inhibition of HIV-1 entry was due to
decreased cellular cholesterol level. Similar effect was
also observed in cells treated with LXR agonist-TO-
901317. The inhibitory effect of TO-901319 on HIV-1
virus entry is consistent with earlier findings [7,43].
Since ATRA and TO-901317 have synergistic effect on
ABCA1 expression and cholesterol traffic, we hypothe-
sized that ATRA and TO-901317 could reduce HIV-1entry synergistically. As expected, virus entry in 1G5
cells treated with both ATRA and TO-901317 was
reduced by 67%.
Next we tested whether ATRA can inhibit HIV-1 repli-
cation in 1G5 cells. The level of luciferase activity in
these cells driven by HIV-1 LTR is proportional to viral
entry, integration, and transcriptional activity. 1G5 cells
were pretreated with ATRA for one day, and then
infected with HIV-1. Infected cells were continuously
cultured in the presence of ATRA for 4 days. Four days
after HIV-1 infection, luciferase activity increased by
more than 10 times compared to uninfected cells (data
not shown), indicating successful virus infection. The
HIV-1 replication level was calculated by the fold change
of luciferase activity after 4 days of infection to the basal
luciferase activity after 2 days of infection. Compared to



































































































Figure 4 (See legend on next page.)
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Figure 4 ATRA and TO-901317 synergistically increase cellular cholesterol efflux. A) ATRA and TO-901317 increased ABCA1 dependent
cholesterol efflux in Jurkat cells. Jurkat cells were treated with 5 μM ATRA, or 5 μM TO-901317 or 5 μM each of ATRA and TO-901317 for 24
hours along with radioactive cholesterol and cholesterol efflux to apo-A1 was estimated after 24 hours of incubation in cholesterol efflux
medium. The results are presented as mean± the standard deviation (SD; n = 3). ** p< 0.01 versus cells treated with DMSO. B-D) Cholesterol
staining with Filipin III. 1G5 cells treated with 5 μM of ATRA and 1 μM of TO-901317 for 3 days and then incubated without (B, C) or with (D)
60 μM of water soluble cholesterol for 30 minutes at 37 °C. Cells were then fixed and stained with Filipin III as described in Methods. Scale bar
5 μm. C) The intensity of cholesterol staining in (B) was analyzed as described in Methods. The relative intensity compared to DMSO treatment
was plotted. Data represents three individual fields with 40–60 cells per field. *p< 0.05; **p< 0.01.
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TO-901317 (Figure 5A). Cell growth and viability were
not affected under these conditions (data not shown).
Based on these data we conclude that ATRA could in-
hibit HIV-1 infection by reducing virus entry and com-
bination of ATRA and TO-901317 has the most
inhibitory effect.
Discussion
Vitamin A plays critical roles in T cell development and
functions. Retinoic acid (RA) and ATRA, metabolites of
vitamin A have been shown to be involved in multiple T
cell effector responses through their binding to RAR, a










































Figure 5 ATRA and TO-901317 inhibit HIV-1 entry and replication. A)
TO-901317. Untreated cells (open bar) or cells treated with reconstituted w
one hour, lysed and the amount of viral DNA was quantified by realtime P
change of viral DNA compared to that from DMSO treatment was plotted.
presented as mean± the standard deviation. *p< 0.05; ** p< 0.01. B) 1G5
infected with HIV-1 and were cultured in presence of ATRA and TO-901317
The infectivity of HIV-1 was calculated by the relative fold change of lucifer
fold change compared to that of DMSO treatment was plotted. The experi
two independent experiments. Data are presented as mean± the standardpresenting cells provide the RA to the antigen primed T
cells and promote the development of Treg cells [44].
Recent data show that RA is involved in development of
both T helper and Treg cells [21,22]. ATRA up-regulates
ABCA1 expression only in activated CD4+ T cells
(Figure 1E), indicating that induction of ABCA1 by
ATRA may play an important role in immune response.
Cellular cholesterol is a component of the plasma
membrane and is also essential in cell proliferation.
Regulation of intracellular cholesterol levels has been
proposed as a mechanism to regulate T cell proliferation
[45]. Intracellular cholesterol level is regulated by two
competing pathways, cholesterol uptake and efflux, and





























1G5 cells were incubated for 3 days in the presence of ATRA or
ater-soluble cholesterol (close bar), were then infected with HIV-1 for
CR using R/U5 primer as described in Methods. The relative fold
The results represent four independent experiments. Data are
cells were pretreated with ATRA or TO-901317 for one day, and then
. Luciferase activity was determined on 2 and 4 days after infection.
ase on day 4 compared to that of basal level on day 2. The relative
ment was performed in triplicates and the result is representative of
deviation. ** p< 0.01 versus cells treated with DMSO.
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induces ABCA1 expression and ABCA1-dependent
cholesterol efflux in activated primary human CD4+ T
cells and Jurkat cells implying that RA could affect T cell
functions by regulating the cellular cholesterol levels.
ATRA is known to induce ABCA1 expression in
macrophages either by RAR/RXR pathway or through
induction of LXR and LXR/RXR pathway [20]. In the
RAR/RXR pathway, ATRA was shown to up-regulate
ABCA1 gene expression through direct binding of RAR/
RXR heterodimers to the DR4 element in the ABCA1
promoter [13]. In the alternate pathway, ATRA up-
regulates LXR, and LXR/RXR heterodimer induces
ABCA1 expression through its interaction with the
ABCA1 promoter [28,46]. Activation of T cells is known
to up regulate LXR level [47], leading to the possibility
that the synergistic effect of ATRA and LXR agonist is
due to the activation of ABCA1 promoter by both RXR/
RAR and RXR/LXR heterodimers in activated T cells.
Cholesterol is an essential component of cell mem-
brane as well as viral membrane. The essential role of
cholesterol in different steps of viral infection and repli-
cation has been demonstrated for a number of viruses
[35,36]. Virus entry is one critical step requiring choles-
terol. For HIV-1, cholesterol in both viral and target cell
membrane is required for successful viral infection
[8,48,49]. Depletion of cholesterol using cyclodextrin
compounds has been demonstrated to have significant
inhibitory effect on HIV-1viral infectivity in vitro [8].
ABCA1 mediated cholesterol efflux has been shown to
inhibit HIV-1 infection in macrophages [6,7]. Our results
show that ATRA mediated induction of ABCA1 and
cholesterol efflux in activated T cells leads to the inhib-
ition of HIV-1 infection. Both the induction of ABCA1
and the cholesterol efflux were further enhanced by LXR
agonist similar to the data shown for macrophages
[16,29,32,33].
ATRA is known to affect HIV-1 replication [37-40].
RA has been shown to inhibit HIV-1 production in sti-
mulated T cell lines [50]. RA inhibited HIV-1 LTR activ-
ity and viral production in monocytes [39,51], and
vitamin A deficiency enhanced the HIV-1 expression in
rat model system [52]. Mechanism of RA mediated in-
hibition of HIV-1 replication is not known. Results pre-
sented here show that ATRA reduced the HIV-1 entry
into CD4+ T cells by ABCA1 mediated cholesterol efflux
and cholesterol replenishment abolished the inhibitory
effect of ATRA (Figure 5B) strongly indicating that
ABCA1 might play a role in this inhibition.
Growing attention has been drawn to dietary and
plant-derived compounds targeting cholesterol and lipid
rafts [53]. Retinoic acids, the bioactive metabolites of
vitamin A, are likely candidates for natural repressors of
HIV-1 in vivo. Vitamin A deficient diet can result inincreased T cell pro-inflammatory responses and HIV-1
expression in HIV-1 transgenic rat [52]. Many HIV-1-
induced diseases, including morbidity, mortality, and the
rate of mother-to-child transmission, are inversely corre-
lated with serum vitamin A levels [54,55]. Vitamin A
supplementation has been shown to reduce HIV-1-
associated disease and to slow the progression toward
AIDS [56,57]. Additionally, retinoic acids appear to be
useful as an adjuvant during vaccination to increase
memory T cell responses and protection from viral infec-
tion at mucosal sites and it may facilitate the develop-
ment of more effective vaccines against pathogens
transmitted through mucus like HIV [58].
Conclusions
In summary, results presented in this report demon-
strated that ATRA specifically up regulated ABCA1 ex-
pression in CD4+ T cells. ATRA and LXR-agonist TO-
901317 have synergistic effect on the induction of
ABCA1 expression as well as anti-HIV-1 infection in
CD4+ T cells. Taken together, retinoic acids along with




Primary human CD4+ T cells were isolated from the
peripheral blood mononuclear cells (PBMCs) of healthy
donors using Dynabeads Untouched Human CD4+ T
cells isolation kit (Invitrogen) following the manufac-
turer's instruction. Cells were cultured in RPMI 1640
supplemented with 10% dialyzed FBS, 100 U/ml peni-
cillin, 100 μg/ml streptomycin, 2 mM L-glutamine,
50 U/ml IL-2 (PeproTech). To activate CD4+ T cells,
cells were primed with anti-CD3 and anti-CD28 anti-
bodies using Dynabeads CD3/CD28 T cell expander
(Invitrogen). Jurkat E6.1 cell line, a CD4+ human T cell
lymphoblast-like cell line, was purchased from ATCC.
The 1G5 cell line, a clonal line derived from Jurkat cells
stably transfected with an LTR (HIV)-luciferase con-
struct was provided by the AIDS Research and Refer-
ence Reagent Program, Division of AIDS, National
Institute of Allergy and Infectious Diseases, National
Institutes of Health [41]. Jurkat cell lines were cultured
as described [59]
Reagents
ATRA, LXR agonist TO-901317, water-soluble choles-
terol, phorbol myristate acetate (PMA), phytohemagglu-
tinin (PHA), and Filipin III were purchased from Sigma-
Aldrich (St. Louis, MO). Antibodies against ABCA1 and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
were purchased from Abcam (Cambridge, MA).
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Total cellular RNA was extracted using RNAqueousW-
4PCR Kit (Invitrogen). To quantitatively analyze gene ex-
pression, 200 ng of total RNA was used to synthesize the
first strand DNA with random primers [59]. The real-time
PCR was performed by using SYBR Green Master Mix
(Qiagen) and the following primers: Abca1-forward 5’-
GGTAGGAGAAAGAGACGCAAACAC-3’ and reverse
5'- AACAAGCCATGTTCCCTCAGC -3'; Abca3- forward
5'- GAGCATCTGAAAGACGCACTGC-3'and reverse 5’
ATCTCTGAAGGACGCTGCCACAAG-3; Abcg1-forward
5’– CCGACCGACGAC ACAGAGA -3’and reverse 5' –
GCACGAGACACCCACAAACC -3’; Abcg4- forward
5' – GAGCCAGGGTCAGTGCATCT -3’, reverse 5' –
GCAAGCCGAGTCCCTTAGA -3’. The quantities of ABCs
mRNAs were normalized by the levels of GAPDH mRNA.
Western blot for ABCA1
Whole cell proteins were extracted using M-PER mam-
malian protein extraction reagent with protease inhibitor
cocktails (Thermo Scientific). Protein extracts were elec-
trophoresed in a 4-12% gradient NuPAGE Bis Tris Gel
(Invitrogen Life Technologies), and transferred to PVDF
membrane and detected with fluorophore-labeled sec-
ondary antibody using Odyssey Infrared Imaging System
(LI-COR Biotechnology).
Cholesterol efflux assay
The assay was performed as described by Costet et al.
[19]. Briefly cells were cholesterol loaded and radiola-
beled for 24 hours in RPMI-1640 medium containing
0.2% bovine serum albumin (BSA), 50 ug/ml of acety-
lated low-density lipoprotein (Biomedical Technologies)
and 1 μCi/ml of [3 H] cholesterol (Perkin Elmer) in the
presence or absence of ATRA or TO-901317. Cells were
washed with PBS, equilibrated for 30 min in RPMI-1640
medium with 0.2% BSA, and then incubated in choles-
terol efflux medium (RPMI-1640 with 0.2% BSA, 5 ug/
ml of purified apoA-1 (EMD Millipore)). For Cholesterol
efflux analysis the samples were collected at 4 hours of
incubation and radioactivity in the medium and cell lys-
ate was counted by liquid scintillation counting. Choles-
terol efflux was calculated as the percentage of the
radioactivity recovered in the medium over the total
radioactivity (cells plus media). Cholesterol efflux assay
was performed in triplicates.
Cholesterol replenishment and staining
To replenish cholesterol, Jurkat cells were incubated
with cholesterol-saturated methyl-β-cyclodextrin at a
concentration of 60 μM cholesterol for 60 minutes at
37 °C and then washed five times with PBS before being
used in cholesterol staining and virus infection.For cholesterol staining cells were allowed to rest in
0.01% poly-l-lysine–coated 8-well chamber slide for
5 min before a short spin, fixed with 3% formaldehyde
(Thermo Scientific) for 1 hr at room temperature,
washed with PBS, and incubated with freshly prepared
Filipin III solution (250 μg/ml in PBS with 1% BSA) for
1 hr. Then, cells were washed with PBS and mounted in
ProLong Anti-fade mounting media (Invitrogen) and
were observed under an inverted two futon fluorescence
microscope (LSM 710, Zeiss) at 720/460 nm with a 60X
immersion lens. Images were acquired and analyzed
using LSM 5 image browser. To measure Filipin III in-
tensity, the total pixel intensity for same number of cells
was recorded after subtracting background using Med-
ical Image Processing, Analysis, and Visualization appli-
cation. Forty to sixty cells were analyzed per view and
three independent views were performed for each
treatment.
HIV-1 infection
1G5 cells were treated with ATRA or TO-901317 for 24
hours and infected with HIV-1 (10 ng of p24/10^6 cells)
by spinoculation at 1200 g for two hours. Cells were
washed extensively and incubated for four days in the
presence of ATRA or TO-901317. Cells were harvested
and the luciferase activity was measured using Luciferase
Assay System [60]. To test HIV-1 virus entry, 1G5 cells
were treated with ATRA and TO-901317 for three days
and were reloaded with or without water-soluble choles-
terol and infected with HIV-1 (10 ng of p24/10^6 cells).
After additional one hour of incubation, cells were har-
vested and early viral DNA was measured by real-time
PCR as described by Popik et al. [42].
Statistical analysis
Statistical analysis was assessed by Student’s t test. A
value of p< 0.05 was considered significant.
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